# Braveheart Bio, Inc. — capital_raise/public_offering [completed]
Source: SEC API (secapi.ai) · situation sit_f6238c7b7b71a4976ea2 · retrieved 2026-08-12T07:00:23.242Z

## Overview
Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases; its lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor being developed for obstructive and non-obstructive HCM.

Braveheart Bio, Inc., a clinical-stage biopharmaceutical company developing BHB-1893, a cardiac myosin inhibitor for hypertrophic cardiomyopathy, is conducting an initial public offering of 21,250,000 shares of common stock at $18.00 per share, generating gross proceeds of $382,500,000. After underwriting discounts and commissions of $26,775,000, net proceeds to the company are approximately $355,725,000. The underwriters have been granted a 30-day option to purchase up to an additional 3,187,500 shares at the IPO price less underwriting discounts. The company's common stock is approved for listing on The Nasdaq Global Market under the symbol "BRVE", with expected delivery of shares on or about August 7, 2026.

## Terms
- Deal value: $382.5M · Consideration: cash · Price/share: $18

## Key dates
- Expected close 2026-08-07 · Completed 2026-08-06

## Timeline
- 2026-08-06 · 424B4 (0001628280-26-054354): 424B4 - Braveheart Bio, Inc. — *Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases; its lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor being developed for obstructive and non-obstructive HCM.* Braveheart Bio, Inc., a clinical-stage biopharmaceutical company developing BHB-1893, a cardiac myosin inhibitor for hypertrophic cardiomyopathy, is conducting an initial public offering of 21,250,000 shares of common stock at $18.00 per share, generating gross proceeds of $382,500,000. After underwriting discounts and commissions of $26,775,000, net proceeds to the company are approximately $355,725,000. The underwriters have been granted a 30-day option to purchase up to an additional 3,187,500 shares at the IPO price less underwriting discounts. The company's common stock is approved for listing on The Nasdaq Global Market under the symbol "BRVE", with expected delivery of shares on or about August 7, 2026.
  https://www.sec.gov/Archives/edgar/data/2131524/0001628280-26-054354.txt

## Citations
- 0001628280-26-054354 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000162828026054354